The study purpose is to determine the safety and efficacy of a belatacept-based
immunosuppressive regimen (calcineurin inhibitor free) with alemtuzumab or rabbit
antithymocyte globulin (rATG) induction and early glucocorticoid withdrawal (CSWD) and a
belatacept-based immunosuppressive regimen with tacrolimus-based regimen with rabbit
antithymocyte globulin induction and early glucocorticoid withdrawal in renal transplant
recipients.
The hypothesis is that a belatacept-based immunosuppressive regimen with alemtuzumab
induction, mycophenolate mofetil (MMF)/mycophenolic acid (MPA), and early glucocorticoid
withdrawal (Group A) in renal transplant recipients or Belatacept-based immunosuppressive
regimen with rabbit antithymocyte globulin induction, MMF/MPA and early glucocorticoid
withdrawal (Group B) will lead to less risk of graft loss, patient death, or reduced renal
function at 12 months as compared to a tacrolimus-based immunosuppressive regimen with rabbit
antithymocyte globulin, MMF/MPA, and early glucocorticoid withdrawal in renal transplant
recipients (Group C).